Table 1.
Type of Candidate Vaccine | Developer (Some Examples) | Stage of Clinical Evaluation |
---|---|---|
DNA | Zydus Cadila Inovio Pharmaceuticals + International Vaccine Institute + Advaccine (Suzhou) Biopharmaceutical AnGes + Takara Bio + Osaka University |
CTRI/2020/07/026352 (phase 2/3) NCT04642638 (phase 2/3) NCT04655625 (phase 3) |
mRNA | BioNTech/Fosun, Pharma/Pfizer (BNT162b2) Moderna (mRNA-1273) |
NCT04368728 (Authorized) NCT04760132 (Authorized) |
Inactivated vaccine | Sinovac Research and Development Co, Ltd. Sinopharm + China National Biotec Group Co + Beijing Institute of Biological Products |
NCT04756830 (Authorized) NCT04863638 (Authorized) |
Live attenuated vaccine | Codagenix/Serum Institute of India Meissa Vaccines, Ins. |
NCT04619628 (Phase 1) NCT04798001 (Phase 1) |
Recombinant protein subunit vaccine | Novavax Sanofi Pasteur + GSK Instituto Finlay de Vacunas Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “vector” Center for Genetic Engineering and Biotechnology (CIGB) |
NCT04611802 (phase 3) PACTR202011523101903 (phase 3) RPCEC00000354 (phase 3) NCT04780035 (phase 3) RPCEC00000359 |
Viral vectors-based vaccines | AstraZeneca + University of Oxford CanSino Biological Ins./Beijing Institute of Biotechnology Gamaleya Research Institute; Health Ministry of the Russian Federation Janssen Pharmaceutical |
NCT04760132 (Authorized) NCT045226990 (Authorized) NCT04530396 (Authorized) NCT04505722 (Authorized) |